Responses
Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1167 Prediction of first-in-human dose for HPN536, a T-cell engager targeting mesothelin: MABEL vs mechanistic translational PK/RO/PA modeling
Compose a Response to This Article
Other responses
No responses have been published for this article.
